Breast cancer is the most common cancer in women, with more than 1.7 million diagnoses worldwide per annum. Metastatic breast cancer remains incurable, and the presence of triple‐negative phenotypes makes targeted treatment impossible. The aryl hydrocarbon receptor (AhR), most commonly associated with the metabolism of xenobiotic ligands, has emerged as a promising biological target for the treatment of this deadly disease. Ligands for the AhR can be classed as exogenous or endogenous and may have agonistic or antagonistic activity. It has been well reported that agonistic ligands may have potent and selective growth inhibition activity in a number of oncogenic cell lines, and one (aminoflavone) has progressed to phase I clinical trials for breast cancer sufferers. In this study, we examine the current state of the literature in this area and elucidate the promising advances that are being made in hijacking the cytosolic‐to‐nuclear pathway of the AhR for the possible future treatment of breast cancer.

中文翻译：

---

芳烃受体（AhR）作为乳腺癌药物靶点。

乳腺癌是女性中最常见的癌症，全世界每年有超过 170 万例确诊病例。转移性乳腺癌仍然无法治愈，三阴性表型的存在使得靶向治疗变得不可能。芳烃受体 (AhR) 最常与异生物质配体的代谢相关，已成为治疗这种致命疾病的有希望的生物靶点。AhR 的配体可分为外源性或内源性，可能具有激动或拮抗活性。据报道，激动性配体在许多致癌细胞系中可能具有强效和选择性的生长抑制活性，其中一种（氨基黄酮）已进入针对乳腺癌患者的 I 期临床试验。在这项研究中，